Cargando…
Heterologous recombinant expression of non-originator NISTmAb
The successful development and regulatory approval of originator and biosimilar therapeutic proteins requires a systems approach to upstream and downstream processing as well as product characterization and quality control. Innovation in process design and control, product characterization strategie...
Autores principales: | Kashi, Lila, Yandrofski, Katharina, Preston, Renae J., Arbogast, Luke W., Giddens, John P., Marino, John P., Schiel, John E., Kelman, Zvi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152460/ https://www.ncbi.nlm.nih.gov/pubmed/29958062 http://dx.doi.org/10.1080/19420862.2018.1486355 |
Ejemplares similares
-
Interlaboratory Studies Using the NISTmAb to Advance Biopharmaceutical Structural Analytics
por: Yandrofski, Katharina, et al.
Publicado: (2022) -
Development of orthogonal NISTmAb size heterogeneity control methods
por: Turner, Abigail, et al.
Publicado: (2018) -
The NISTmAb Reference Material 8671 value assignment, homogeneity, and stability
por: Schiel, John E., et al.
Publicado: (2018) -
Qualification of NISTmAb charge heterogeneity control assays
por: Turner, Abigail, et al.
Publicado: (2018) -
The NISTmAb Reference Material 8671 lifecycle management and quality plan
por: Schiel, John E., et al.
Publicado: (2018)